Asia Pacific Insulin Market Registering At USD 15.04 Billion By 2020


 San Francisco, 16 Dec 2020: The Report Asia Pacific Insulin Market By Product (Rapid Acting, Short Acting, Pre-Mixed, Long Acting) ,By Application (Type I & II Diabetes ),By Source( Analogs & Recombinant Insulin) And Segment Forecasts To 2020

The Asia Pacific insulin market is expected to reach USD 15.04 billion by 2020, according to a new study by Grand View Research, Inc. Growing regional prevalence of diabetes, increasing market penetration rates of modern insulin products in emerging markets such as India and China is expected to drive market growth during the forecast period. Furthermore, patent expiration of key products such as Lantus is expected to trigger the manufacturing of biosimilars from local manufacturers such as Biocon.

Long-acting analog dominated the overall market in terms of revenue share in 2013, with revenue estimated at USD 2,051.9 million. High prices coupled with relatively higher efficacies exhibited by these products account for its large share. Rapid-acting analogs followed the long-acting segment in 2013 accounting for a revenue share of over 25.0% on account of their high market penetration rates in developed markets such as Australia and Japan.

Access Research Report of Asia Pacific Insulin Market @ https://www.grandviewresearch.com/industry-analysis/asia-pacific-insulin-market

Further key findings from the study suggest:

  • The analogs source segment accounted for the largest revenue share in 2013 was valued at USD 3,441.7 million. Growing demand for analogs in emerging markets with high unmet medical needs such as China and India is one of the major factors attributing to its large share.
  • Japan, on behalf of its sophisticated healthcare infrastructure, high patient awareness, and disposable income levels dominated the market in 2013 with a revenue share of over 38.0%.
  • China on the other hand is expected to register the highest CAGR of 21.1% during the forecast period owing to the growing prevalence of type I and type diabetes and the expected decline in insulin prices as a result of continued initiatives to improve healthcare access.
  • The Asia Pacific insulin market is oligopolistic in nature and is dominated by three key players including Novo Nordisk, Eli Lilly, and Sanofi Aventis.

 

Access Press Release of Asia Pacific Insulin Market @ https://www.grandviewresearch.com/press-release/asia-pacific-insulin

 

Comments

Post a Comment

Popular posts from this blog

Asia Pacific PoC Diagnostics Market Growth Opportunities, Industry Analysis And Forecast: Grand View Research Inc.

Image
San Francisco, 18 March 2020 :  The Report   Asia Pacific PoC Diagnostics Market  Analysis And Segment Forecasts To 2020 The Asia Pacific point of care (PoC) diagnostics market is expected to reach USD 5,427.1 million by 2020, according to a new study by Grand View Research, Inc. Growing base of geriatric population and the ability to render immediate results and improve patient care coupled with rising market penetration of PACS (picture archiving and communication systems) and EMR (electronic medical records) are expected to drive demand over the next six years. Skilled staff shortages, especially pertaining to the field of diagnostics are also expected to accelerate the market penetration rates of PoC products, by expediting lab automation processes. Rising demand for home healthcare and other healthcare establishments catering to the elderly population and initiatives undertaken by governments to shorten hospital stays by establishing out-patient care models are also expect
Read more

Biomaterials Market Size Poised To Reach USD 348.4 Billion By 2027

Image
  San Francisco, 15 Dec 2020:   The Report  Biomaterials Market  Size, Share & Trends Analysis Report By Product (Natural, Metallic, Polymer), By Application (Cardiovascular, Orthopedics, Plastic Surgery), By Region, And Segment Forecasts, 2020 - 2027 The global biomaterials market size is expected to reach USD 348.4 billion by 2027, registering a CAGR of 15.9% over the forecast period, according to a new report by Grand View Research, Inc. The application of biomaterials represents a fast-growing field in biomedical research. Recent advances in the improvement of bioactivity, compatibility, and mechanical properties of biomaterials have introduced new opportunities for their application in tissue engineering, immune engineering, and drug delivery systems. Biocompatibility, low toxicity, and renewable nature of polymeric biomaterials make them potent drug delivery agents in controlled and targeted drug delivery, thus providing lucrative opportunities for the market growth. The adve
Read more

Latin America Nutrition & Dietary Supplements Market Expected To Grow At A CAGR 8.8% For The Forecast Period From 2017 To 2025 : Grand View Research Inc.

San Francisco, 20 May 2019:  The Report  Latin America Nutrition & Dietary Supplements Market  Size, Share & Trends Analysis Report By Formulation, By Function (Medical Foods, Sports Nutrition), By Consumer, By Country, And Segment Forecasts, 2018 – 2025 The Latin America Nutrition & Dietary Supplements Market size is expected to reach USD 47.5 billion by 2025, according to a new report by Grand View Research, Inc. It is anticipated to expand at a CAGR of 8.8% over the forecast period. Growing expenditure on nutrition and dietary supplements, disposable income, and consumer awareness are some of the key market drivers. Changing regulatory framework to ensure drug safety in Latin American countries such as Mexico and Argentina is also expected to positively impact market growth in the forthcoming years. Growing demand for nutrition and dietary supplements among geriatric population is also one of the considerable market drivers. Nutrition plays a vital role in maintain
Read more